TriMix-MEL (ECI-003), a rationally designed mRNA immunotherapy based on the unique TriMix platform, starts Phase Ib trial in adjuvant melanoma patients
Niel (Belgium), 30 June 2017 – eTheRNA immunotherapies, a clinical-stage company developing mRNA based cancer immunotherapies from its unique TriMix platform, announces the start of the first Phase Ib oncology clinical study evaluating its novel candidate TriMix-MEL (ECI-006) in metastatic melanoma patients showing no evidence of disease after surgical removal of their tumor, but at risk for disease recurrence.
Exploring synergies between PCI and TriMix technologies to further enhance the effect of novel oncologic therapies
Oslo (Norway) and Niel (Belgium), 8 December 2016 — PCI Biotech (OSE: PCIB), a cancer focused biopharmaceutical company, and eTheRNA immunotherapies NV, a VUB spin-off company backed by strong life science investors to continue the development of mRNA-based immunotherapies, today announced that they are initiating a preclinical research collaboration.
Appointment of highly reputed chairman marks eTheRNA’s ambitions in the cancer immunotherapy area
Niel (Belgium), 14 September 2016 — eTheRNA immunotherapies NV, the VUB spin-off that recently secured a EUR 24 million investment to continue the development of mRNA-based immunotherapies, has appointed Dr. Russell G. Greig as Chairman of the Board. Dr. Greig’s mandate as chairman has become effective as of September 13, 2016.
eTheRNA is on track to move the mRNA production unit from Jette to Niel in 2017 and to triple its capacity
Brussels (Belgium), 4 August 2016 — eTheRNA immunotherapies NV, the VUB spin-off that recently secured a EUR 24 million investment to continue the development of mRNA-based immunotherapies, has strengthened its management team with the appointment of Alain Deloof (foto) as Production Lead , effective August 1, 2016.